Latest - Page 2 of 4 - Rivervest - News & Press / Case Studies / Articles

News & Press

RiverVest Mourns Passing of Co-Founder Andrew B. Craig III

News & Press

RiverVest Builds Another San Diego Based Biopharma Company

News & Press

Sivan Weitzman Joins RiverVest Venture Partners as CFO

News & Press

RiverVest Venture Partners Closes on Oversubscribed $184.4 Million Life Science Fund

News & Press

RiverVest Venture Partners’ Portfolio Company Securus Sold to Boston Scientific Represents 9th Exit from RiverVest Venture Fund II

News & Press

RiverVest Venture Partners Expands Scientific Advisory Board

Wugen Raises $172 Million to Advance Clinical State Memory NK Cell Platform, Progress Best-In-Class AML Program, and Initiate Multiple Solid Tumor Trials – 7/15/2021
Neuros Medical Receives FDA Breakthrough Device Designation for its Novel Altius® High Frequency Nerve Block System – 06/29/2021
Glycomine’s Natural History Study Informs Potentially Lifesaving Update to Standard of Care for PMM2-CDG Patients – 6/29/2021
Mirum Pharmaceuticals Presents Analyses From Its Rare Disease Programs at the EASL International Liver Congress 2021 – 6/23/2021
Spruce Biosciences Announces Publication Of Phase 2 Results For Tildacerfont In Journal Of Clinical Endocrinology And Metabolism – 6/21/2021
Xilio Therapeutics Announces FDA Acceptance of IND Application for XTX101 for the Treatment of Solid Tumors – 6/17/2021
Standard Bariatrics Secures $35M in Series B Funding to Accelerate Development and Commercialization of Their First Bariatric Surgical Platform for Sleeve Gastrectomy – 6/1/2021
Spruce Biosciences Presents Phase 2 Data for Tildacerfont in Adults with Congenital Adrenal Hyperplasia at 23rd European Congress of Endocrinology – 5/24/2021
New Allakos Data Presented at DDW 2021 Suggest that Eosinophilic Gastritis and/or Eosinophilic Duodenitis (EG/EoD) is Highly Underdiagnosed and may be a Common Cause of Moderate-to-Severe Gastrointestinal Symptoms – 5/24/2021
Sparrow Pharmaceuticals Presents Data on SPI-62 at the European Congress of Endocrinology – 5/22/2021
Reneo Pharmaceuticals Reports First Quarter 2021 Financial Results – 5/20/2021
Sparrow Pharmaceuticals Secures $50 Million Series A Financing – 5/18/2021
Spruce Biosciences Reports First Quarter 2021 Financial Results and Provides Corporate Updates – 5/12/2021
Xilio Therapeutics Presents Preclinical Tumor-Selective Activity and Tolerability Data for XTX101 at
Frontiers in Cancer Immunotherapy Virtual Symposium – 5/12/2021
OncoResponse Appoints Chris Russell as Chief Financial Officer – 5/11/2021
Allakos Reports First Quarter 2021 Financial Results and Provides Business Update – 5/10/2021
Mirum Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update – 5/6/2021
Standard Bariatrics® Titan SGS Stapling Technology for Sleeve Gastrectomy Receives FDA Clearance – 5/4/2021
Mirum Pharmaceuticals and CANbridge Pharmaceuticals Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat in Greater China for Rare Liver Diseases – 4/29/2021
Pfizer Acquires Amplyx Pharmaceuticals – 4/28/2021
Arch Oncology Secures $105 Million Series C Financing – 4/27/2021
Mirum Pharmaceuticals Receives Notice of Allowance for Methods of Use Patent for Maralixibat in Alagille Syndrome – 4/26/2021
Wugen Appoints Daniel Kemp Ph.D., as Chief Executive Officer – 4/14/2021
Cardialen Announces Positive Results from Low-Voltage MultiPulse Therapy to Terminate Atrial Fibrillation – 4/13/2021
Mirum Pharmaceuticals and Vivet Therapeutics Enter into Exclusive Worldwide Option and License Agreement for Vivet’s Gene Therapy Programs Targeting Progressive Familial Intrahepatic Cholestatis – 4/12/2021
Arch Oncology Presents New Preclinical T-ALL Data on Highly Differentiated Anti-CD47 Antibody AO-176 – 4/10/2021
Reneo Pharmaceuticals Announces Pricing of Initial Public Offering – 4/8/2021
OncoResponse Raises $40.6 Million in Series C Financing – 3/31/2021
Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the 2021 DDW Annual Meeting – 3/30/2021
Xilio Therapeutics Strengthens Leadership Team with the Addition of Two Executives – 3/29/2021
Mirum Pharmaceuticals Announces FDA Acceptance of the New Drug Application and Priority Review for Maralixibat in Alagille Syndrome – 3/29/2021
Spruce Biosciences Presents Phase 1 and 2 Data for Tildacerfont in Adults with Congenital Adrenal Hyperplasia from Endocrine Society’s 2021 Annual Meeting – 3/17/2021
Reneo Pharmaceuticals Appoints Eric Dube, Ph.D. to its Board of Directors – 3/15/2021
Arch Oncology Announces Two New Preclinical Data Presentations on Highly Differentiated Anti-CD47 Antibody AO-176 at AACR 2021 – 3/10/2021
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) – 3/10/2021
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2020 Results and Provides Business Updates – 3/9/2021
Wugen Announces Exclusive Partnership Agreement With Alpha Biopharma in Asia for Cell Therapies to Treat Cancer – 3/8/2021
Spruce Biosciences to Announce Phase 1 and 2 Data of Tildacerfont at Endocrine Society’s 2021 Annual Meeting – 3/2/2021